Cite
HARVARD Citation
Galassi, A. et al. (2021). Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency. Expert opinion on drug safety. 20 (11), pp. 1333-1349. [Online].